BOT 16.9% 38.0¢ botanix pharmaceuticals ltd

Acne Phase 2 - Probability of Success and Likely Market Response, page-28

  1. 800 Posts.
    lightbulb Created with Sketch. 383
    Not at all.

    BOT is progressing into phase 2 with drugs tested already in humans. biopsies taken and validated for changes in gene expression. they know the mechanism of action and consequently that BTX potentially down-regulates these. not to mention the added anti-microbial benefits.

    PAB And PAA are firstly both cancer based bio specs. they have used animal models to test their drug in phase 1 trials, with some explants of biopsies. they have not identified the conditions of explant culture either, which may also contribute to the replication to human models.

    strategies are different. you can see that BOT have a clear newsflow and have already done a lot of the hard lifting prior to phase 2 to derisk the company. PAA And PAB haven't. it's more of a whim on phase 1 results. they could be good, they could be poor.

    no hiding upside with cancer is huge. but the risk of success is far greater.

    quite different stories.

    I can write more. on my phone.

    all the best,
    zabba
    Last edited by zabba198: 28/07/19
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.